Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111
Cancer Survival Analysis01:21

Cancer Survival Analysis

319
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
319
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

British journal of cancer·2026
Same author

Patient-Reported Outcomes to Inform Tolerability Characterization in Cancer Trials: A Critical Perspective on Unresolved Methodological Issues.

Cancer control : journal of the Moffitt Cancer Center·2026
Same author

Fatigue Experience in Oncology; a Targeted Qualitative Literature Review and Novel Patient-Centric Conceptual Model.

Advances in therapy·2025
Same author

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Implementing sensor-based digital health technologies in clinical trials: Key considerations from the eCOA Consortium.

Clinical and translational science·2024

Related Experiment Video

Updated: May 24, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials.

Bill Byrom1, Anthony Everhart1, Paul Cordero2

  • 1Science and Medicine, Signant Health, 785 Arbor Way, Blue Bell, PA, 19422, United States, 44 20 4526 1340.

JMIR Cancer
|February 28, 2025
PubMed
Summary
This summary is machine-generated.

Patient-reported outcomes are crucial for early phase oncology trials to understand dose toxicity and select optimal drug doses. This paper advocates for their inclusion and electronic data collection in early drug development.

Keywords:
Common Terminology Criteria for Adverse EventsPROPRO-CTCAEadverse eventscancer trialschemotherapy drugclinical trialscytotoxiccytotoxic chemotherapy drugsdose findingdose leveldose toxicitydrug developmentePROearly phaseelectronic collectionelectronic patient-reported outcomelife-threatening diseaseoncologyoptimal dosepatient-reported outcomepharmacodynamictolerability

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Related Experiment Videos

Last Updated: May 24, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.3K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.0K

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Patient-Reported Outcomes

Background:

  • Patient-reported outcome measures (PROMs) are standard in Phase 3 trials but underutilized in early phase studies.
  • The patient's perspective is essential for evaluating dose toxicity and determining optimal drug dosages.
  • Early phase oncology drug development often lacks comprehensive patient-reported data.

Purpose of the Study:

  • To review the rationale for incorporating patient-reported outcome data into early phase oncology trials.
  • To outline practical approaches for collecting patient-reported outcome data in early phase oncology.
  • To discuss the benefits of electronic data collection for patient-reported outcomes.

Main Methods:

  • This is a viewpoint paper, not a primary research study.
  • It involves a review of existing literature and expert opinion on PROMs in early phase oncology.
  • Discussion focuses on the strategic implementation of PROMs.

Main Results:

  • Early phase trials can benefit significantly from patient-reported outcome data.
  • Integrating PROMs aids in a more complete understanding of dose-limiting toxicities.
  • Electronic data capture offers efficiency and improved data quality for PROMs.

Conclusions:

  • Patient-reported outcomes should be systematically collected in early phase oncology trials.
  • The patient's experience provides critical insights beyond traditional clinical assessments.
  • Electronic methods enhance the feasibility and value of collecting patient-reported outcome data early in drug development.